FBT News and Press, First Trust Amex Biotech Index Fund From 03/18/22

The SPDR S&P Biotech ETF (NYSEARCA:XBI) is on pace for its best trading week in 21 months as the exchange traded fund earlier this week hit a 23-month trading low. XBI is now +8.2% and +2.6% for the day. The biotech fund had not seen such bullish weekly moves since Jun...

The XBI biotech index peaked early last year, and it's now back to where it was in April of 2020. The biopharma stocks got powerfully inflated during 2020 by the pandemic. The biotech stocks are going to need some good news to get moving again. For further details see: B...

Inflation and its implications for real economic growth are the main portfolio positioning consideration of the conflict in Ukraine. On the 8th of March, the U.S. sanctioned Russian energy imports, giving companies 45 days to comply. Higher commodity prices are not the only factor...

FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...

The pandemic has demonstrated how drugmakers can quickly and effectively harness medical innovations. Advances in genetic sequencing underpin many advancements in life sciences, and the sequencing of millions of DNA codes has become cheaper and easier. Given the remarkable groundb...

Almost every commodity rose in prices last week, as did the dollar. Those two factors - rising dollar and rising commodity prices - mean the likelihood of recession in the coming year has risen significantly in just the last week. There was considerable volatility in stocks last week,...

We think that the inflection point is now. The past 18 months have accelerated the use of technology both on the consumer and business side - whether it’s in e-commerce, digital banking, or clean energy. Companies that do not have sunk capital in legacy business models are ofte...

Russia’s invasion of Ukraine, the biggest conventional military attack in Europe since World War II, has wide-ranging implications for economies and markets around the world. Disruptions from this war and the higher energy prices that result could significantly dampen Europe&#x...

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...